Palbo 125 mg (Palbociclib) Capsules

Palbo-125 (Palbociclib 125 mg) is a targeted anticancer medicine primarily used in the treatment of hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. When combined with endocrine therapy, it helps slow the growth and spread of cancer cells by inhibiting key proteins involved in cell division.

Therapeutic Effects:

• Helps delay the progression of advanced breast cancer.
• Reduces the rate of cancer cell multiplication.
• Enhances the effectiveness of hormone therapy.
• Supports long-term disease management in eligible patients.

Active Ingredient:

• Palbociclib USP – 125 mg

Dosage Form:

• Hard Capsule

Composition:
Each capsule contains Palbociclib 125 mg as the active pharmaceutical ingredient along with pharmaceutical-grade excipients used for capsule formulation and stability.

Recommended Adult Dose:

• One 125 mg capsule once daily for 21 consecutive days, followed by 7 days off treatment to complete a 28-day cycle.
• Treatment is generally administered in combination with prescribed endocrine therapy as directed by a healthcare professional.

Administration Guidelines:

• Take the capsule at approximately the same time each day.
• Swallow the capsule whole with water.
• Do not crush, chew, or open the capsule.
• May be taken with food unless otherwise directed by the physician.

Missed Dose:

• If a dose is missed or vomiting occurs after taking a dose, do not take an additional capsule on the same day.
• Resume the next scheduled dose at the regular time.

Important Instructions:

• Use only under the supervision of an oncology specialist.
• Regular blood count monitoring may be required during treatment.
• Dose adjustments may be necessary based on tolerability and laboratory findings.
• Continue treatment for the duration recommended by the treating physician.

Note: Dosage may vary according to individual patient condition, treatment response, and physician assessment. Always follow the prescribed treatment plan.